PANDAA qDx™ SARS-CoV-2 is comprised of a single reaction mix containing reagents to amplify, detect and quantify targets within the SARS-CoV-2 genome. Two SARS-CoV-2 targets, located in the N gene and RdRp gene, respectively, are amplified by distinct PANDAA primer sets and detected by FAM™-labelled hydrolysis probes. An Internal Control (IC) target is amplified by PANDAA primers and reported using a VIC®-labelled hydrolysis probe.
PANDAA sensitivity is not compromised by mutations found in patient samples and has no loss in performance with the B.1.1.7 (UK), B1.351 (South Africa) or P.1 (Brazil) variants. We continue to actively monitor for the emergence mutations in our assay targets and proactively evaluate changes in performance.
For Research Use Only. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). This product is covered by one or more patents, trademarks and/or copyrights owned or controlled by Aldatu Biosciences, Inc.
| Contents | Volume (µL) |
| PRxB Buffer | 2,100 µL |
| SARS-CoV-2 PANDAA | 65 µL |
| RT Enzyme | 5 µL |
| Internal Control RNA | 120 µL |
| Positive Control | 50 µL |
| Negative Control | 50 µL |